S. 2407 · 118th Congress · Health
Treat and Reduce Obesity Act of 2023
- IntroducedJul 20, 2023 Done
- CommitteeDied Jan 3, 2025 Stopped here
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill expands Medicare coverage of intensive behavioral therapy for obesity. Specifically, the bill allows coverage for therapy that is provided by (1) a physician who is not a primary care physician; or (2) other health care providers (e.g., physician assistants and nurse practitioners) and approved counseling programs, if provided upon a referral from, and in coordination with, a physician or primary care practitioner. Currently, such therapy is covered only if provided by a primary care practitioner.
The bill also allows coverage under Medicare's prescription drug benefit of drugs used for the treatment of obesity or for weight loss management for individuals who are overweight.
Congressional Research Service · summary of “Introduced in Senate” version · Jul 20, 2023
Who lobbies on it
13 organizations · 82 filings · Q3 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
America's Health Insurance Plans Inc (ahip)
6 of 6 quarters
“Draft, Allowing Stand-Alone Supplemental Insurance Products to Be Sold on the ACA Individual Market (no bill number) - Sen. Wicker, Roger - supplement product insurance H.R. 4818 - Treat and Reduce Obesity Act - Rep. Wenstrup, Brad - weight loss coverage H.R. 6860 - Restore Protections for Dialysis Patients Act - Rep.…”
-
Amgen Inc
6 of 6 quarters
“Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830…”
-
Eli Lilly & Company
6 of 6 quarters
“General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of…”
10 more organizations, every filingPROUpgrade
Organizations that named S. 2407 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
2 actions · newest first- Jul 20, 2023Read twice and referred to the Committee on Finance.
- Jul 20, 2023Introduced in Senate